Altimmune Pemvidutide IMPACT 48-Week Analysis Selected as 'Best of EASL 2026' — Top-Tier Designation Among MASH Peptide Programs at the Meeting
Altimmune confirmed the IMPACT Phase 2b 48-week analysis on pemvidutide in MASH was selected as a 'Best of EASL 2026' abstract — the highest-tier curated designation at the European Association for the Study of the Liver Congress. The oral presentation is scheduled Thursday May 28 at 17:00 CEST in Barcelona, complementing the late-breaking fibrosis-regression poster Wednesday May 27 08:30 CEST. The 'Best of EASL' selection elevates pemvidutide relative to the broader MASH-peptide slate at the meeting (Novo Nordisk's ESSENCE semaglutide liver safety, Boehringer Ingelheim's survodutide SYNCHRONIZE-1 forward-look, Madrigal's Rezdiffra portal hypertension data) and is the meeting committee's editorial signal that the IMPACT Phase 2b data set is among the highest-impact contributions to the congress.